Core Viewpoint - PMGC Holdings Inc. will implement a 1-for-7 reverse stock split effective March 10, 2025, to comply with Nasdaq listing requirements and enhance its market presence [1][3]. Group 1: Purpose and Compliance - The reverse stock split is essential for PMGC to meet Nasdaq's listing requirements, thereby maintaining its visibility and investor confidence [3]. - Recent Nasdaq rule changes necessitate this action to ensure compliance, particularly regarding maintaining a stable share price above the minimum threshold [4]. Group 2: Impact on Shareholders - Every 7 shares of common stock will consolidate into one share automatically, with no action required from shareholders [7]. - Fractional shares will be rounded up to one full share, and the trading symbol will remain "ELAB" with a new CUSIP number assigned [7]. - Adjustments will be made to outstanding stock awards, options, and warrants to reflect the reverse split [7]. Group 3: Post-Split Structure - After the split, approximately 577,000 shares of common stock will be issued and outstanding [9]. - The total number of authorized shares will also decrease at the same 1-for-7 ratio, eliminating the need for shareholder approval [9].

Core Insights - PMGC Holdings Inc. has announced its annual sponsorship of TCA Venture Group's Orange County network for 2025, aiming to enhance its investment and M&A opportunities while supporting local business growth [1][5] - TCA Venture Group is recognized as one of the largest and most active angel investor networks in the U.S., having invested over $300 million in more than 525 companies since its inception in 1997 [2][4] - The collaboration with TCA is expected to provide PMGC with access to a vast network of over 400 seasoned investors and industry professionals, enhancing its acquisition strategy and portfolio expansion [4][5] Company Overview - PMGC Holdings Inc. is a diversified holding company managing a portfolio through strategic acquisitions and investments across various industries, currently comprising three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [6] - Northstrive Biosciences Inc. focuses on developing aesthetic medicines, particularly addressing obesity through innovative probiotic approaches [7] - PMGC Research Inc. is engaged in R&D, leveraging Canadian research grants to accelerate scientific discovery [7] - PMGC Capital LLC operates as a multi-strategy investment firm, targeting undervalued companies and assets for sustainable growth [7] TCA Venture Group Overview - TCA Venture Group, formerly known as Tech Coast Angels, has a history of over 25 years in funding early-stage companies across innovation-driven industries, having attracted an additional $2.2 billion in follow-on investments from venture capital firms [2][4] - TCA members provide not only capital but also mentorship, board representation, and strategic partnerships, contributing significantly to the entrepreneurial ecosystem in Southern California [4][8] - TCA has been ranked as the 2 U.S. angel investment network for funded deals and recognized for its network centrality by CB Insights [4]

Core Viewpoint - PMGC Holdings Inc. has announced an update on its capital structure, emphasizing its strong financial position and commitment to strategic priorities through its subsidiaries [1][2]. Capital Structure and Financial Position - As of February 25, 2025, PMGC's capital structure includes 4,042,295 common shares outstanding, 4,931 stock options with a weighted-average exercise price of $304 per share, and 979,814 warrants with a weighted-average exercise price of $4.91 per share [5]. - The company has zero debt, indicating a strong balance sheet [5]. - Recent capital raises include $8.0 million from an S-1 offering in September 2024 and approximately $1.9 million from a warrant inducement offering in January 2025 [5]. Subsidiaries and Business Focus - PMGC Holdings operates through three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [3]. - Northstrive Biosciences focuses on developing aesthetic medicines, particularly targeting obesity treatment with its lead asset, EL-22 [5]. - PMGC Research is dedicated to R&D, leveraging Canadian research grants and partnerships with universities to commercialize technologies [5]. - PMGC Capital is a multi-strategy investment firm that seeks undervalued companies and assets to drive sustainable growth [5].

NorthStrive A PMGC HOLDINGS COMPANY (NASDAQ: ELAB) PIONEERING AESTHETIC MEDICINE DISCLAIMERS & FORWARD LOOKING STATEMENTS Any farward-looling statement made by us is based upan the reasonable judgment of our management at the time such statement is made and speals only as of the date on which it is made. Factors or events that could cousse our actual results to differ may emerge from time to time, and it is not possible for us to predict all of the We undertake no obligation to update any forward-looking st ...

Core Viewpoint - Northstrive Biosciences Inc. is advancing its obesity treatment candidates, EL-22 and EL-32, focusing on fat loss while preserving muscle mass, with plans for regulatory meetings and clinical trials in 2025 [1][4][6]. Group 1: EL-22 Development - Northstrive is preparing for a Type B pre-IND meeting with the FDA in Q2 2025, having completed necessary translations and compiled data from its South Korean partner [2][3]. - EL-22 is a novel engineered probiotic targeting the myostatin pathway, showing significant improvements in preclinical studies and safety in a Phase 1 trial in South Korea [3][4]. - The company aims to file an Investigational New Drug application in 2025 to initiate clinical trials combining EL-22 with GLP-1 receptor agonists for obesity treatment [4][8]. Group 2: EL-32 Development - Northstrive has engaged a leading CRO for a preclinical study of EL-32, which expresses dual myostatin and activin-A inhibitors, focusing on glycemic control and body composition in diet-induced obese mice [5][8]. - The study will evaluate EL-32 both as a monotherapy and in combination with the GLP-1 receptor agonist semaglutide [5]. Group 3: Upcoming Presentation - Northstrive will present its obesity drug candidates at the UCLA Obesity Symposium on February 7, 2025, highlighting the muscle-preserving therapeutic potential of its myostatin-engineered probiotics [6]. Group 4: Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., focusing on innovative treatments for obesity while preserving muscle mass during weight loss therapies [7][8].

Core Insights - PMGC Holdings Inc. has initiated strategic investments in fire prevention technology and the U.S. uranium energy market, highlighting its commitment to financing innovation in essential industries with significant growth potential [1][2] Investment Focus - The company believes there is a growing demand for sustainable energy solutions and innovative fire prevention technologies, with investments in uranium exploration supporting nuclear energy as a clean power source to reduce carbon emissions [2] - In the fire prevention sector, PMGC has invested in a U.S.-based company that is developing environmentally friendly technologies aimed at preventing fire ignition and spread, which could provide long-term solutions for saving lives and protecting real estate [3] Portfolio Management - PMGC is dedicated to keeping shareholders informed as its portfolio expands, with a commitment to report any individual investment that exceeds a 4.9% ownership threshold in compliance with SEC regulations [4] - PMGC Capital LLC operates as a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets, aiming to identify high-potential opportunities for sustainable growth and maximizing returns [5] Company Overview - PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries, currently comprising three wholly owned subsidiaries [6]

Core Insights - PMGC Holdings Inc. announced a research agreement with a leading preclinical CRO to evaluate EL-32, a novel engineered probiotic, for its potential in treating obesity [1][4] - The study will assess EL-32's effects on glycemic control and body composition in diet-induced obese mice, both as a monotherapy and in combination with semaglutide [1][5] - EL-32 targets myostatin and activin-A pathways, aiming to preserve muscle mass while reducing fat mass, addressing a critical need in obesity treatment [2][4][3] Company Overview - Northstrive Biosciences Inc., a subsidiary of PMGC Holdings, focuses on developing innovative solutions for obesity treatment, particularly through engineered probiotics [7] - The lead candidate, EL-32, is designed to work alongside existing GLP-1 receptor agonists, which have been shown to cause significant muscle mass loss during weight loss [2][3][4] - PMGC Holdings operates a diversified portfolio, including Northstrive Biosciences, PMGC Research, and PMGC Capital, aiming to maximize growth across various sectors [9]

New York, New York, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the completion of the previously announced warrant inducement with existing institutional investors for its client PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the "Company" or "PMGC") (NASDAQ:ELAB), a diversified holding company, for the exercise of certain outstanding Series A warran ...

Warrant Inducement Agreement - PMGC Holdings Inc has entered into a warrant inducement agreement with existing institutional investors for the exercise of certain outstanding Series A warrants [1] - The investors agreed to exercise the outstanding warrants to purchase 969,385 shares of the company's common stock at an amended exercise price of $2 00 [1] - The gross proceeds from the exercise of the warrants are expected to be approximately $1 9 million [1] - The closing of the warrant inducement transactions is expected to occur on or about January 28, 2025 [2] New Warrants Issuance - In consideration for the exercise of the warrants, the company agreed to issue new warrants to purchase an aggregate of 969,385 shares of common stock with an exercise price of $2 75 per share [3] - The new warrants are exercisable upon shareholder approval and will expire five years from the date of shareholder approval [3] - The company has agreed to file a registration statement within 30 days with the SEC covering the resale of the shares issuable upon exercise of the new warrants [3] Company Overview - PMGC Holdings Inc is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries [5] - The company's portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc, PMGC Research Inc, and PMGC Capital LLC [5]

Northstrive Biosciences Inc. was invited to present EL-22, a novel myostatin asset aimed at preserving muscle while on weight loss treatments, at the UCLA Obesity Symposium called Anti-Obesity Treatments: Challenges and Emerging Solutions, organized by UCLA Metabolism Theme. This is an invite only event that brings together industry leading voices in the obesity space.NEWPORT BEACH, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: EL ...